Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.

Détails

ID Serval
serval:BIB_4965E3E471A7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
Périodique
Pharmacopsychiatry
Auteur⸱e⸱s
Hiemke Christoph, Bergemann Niels, Clement Hans-Willi, Conca Andreas, Deckert Jürgen, Domschke Katharina, Eckermann Gabriel, Egberts Karin, Gerlach Manfred, Greiner Christine, Gründer Gerhard, Haen E.kkehard, Havemann-Reinecke Ursula, Hefner Gudrun, Helmer Renate, Janssen Ger, Jaquenoud Eveline, Laux Gerd, Messer Thomas, Mössner Rainald, Müller Matthias J., Paulzen Michael, Pfuhlmann Bruno, Riederer Peter, Saria Alois, Schoppek Bernd, Schoretsanitis Georgios, Schwarz Markus J., Gracia Silva Margarthe, Stegmann Benedikt, Steimer Werner, Stingl Julia .C., Uhr Manfred, Ulrich Sven, Unterecker Stefan, Waschgler Roland, Zernig Gerald, Zurek Gabriela, Baumann Pierre
ISSN
1439-0795 (Electronic)
ISSN-L
0176-3679
Statut éditorial
Publié
Date de publication
01/2018
Peer-reviewed
Oui
Volume
51
Numéro
1-02
Pages
9-62
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug-drug interactions are typical indications for TDM. However, the potential benefits of TDM to optimize pharmacotherapy can only be obtained if the method is adequately integrated in the clinical treatment process. To supply treating physicians and laboratories with valid information on TDM, the TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued their first guidelines for TDM in psychiatry in 2004. After an update in 2011, it was time for the next update. Following the new guidelines holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs.
Pubmed
Web of science
Open Access
Oui
Création de la notice
02/10/2017 9:44
Dernière modification de la notice
17/01/2021 7:28
Données d'usage